E
Enanta Pharmaceuticals, Inc. (ENTA)
NMS – Real Time Price. Currency in USD
14.53
-0.93 (-6.02%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
14.53
-0.93 (-6.02%)
At close: May 12, 2026, 4:00 PM EDT
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Jay R. Luly Ph.D. | President, CEO & Director |
| Dr. Scott T. Rottinghaus M.D. | Chief Medical Officer |
| Dr. Yat Sun Or Ph.D. | Chief Scientific Officer |
| Mr. Brendan Luu | Chief Business Officer |
| Mr. Harry R. Trout III | VP of Finance & Interim Principal Financial Officer |
| Mr. Matthew P. Kowalsky J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Nathaniel S. Gardiner J.D. | Consultant |
| Ms. Jennifer Viera | Executive Director of Investor Relations & Corporate Communications |
| Ms. Kathleen S. Capps CPA | Executive Director of Accounting, Controller & Interim Principal Accounting Officer |
| Ms. Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | enta-20260511.htm |
| 2026-03-26 | 8-K | enta-20260320.htm |
| 2026-03-12 | 8-K | enta-20260311.htm |
| 2026-02-11 | S-3 | d107341ds3.htm |
| 2026-02-11 | 10-Q | enta-20251231.htm |
| 2026-02-09 | 8-K | enta-20260209.htm |
| 2026-01-26 | DEFA14A | d26790ddefa14a.htm |
| 2025-11-19 | 10-K | enta-20250930.htm |
| 2025-11-17 | 8-K | enta-20251117.htm |
| 2025-10-01 | 8-K | d81869d8k.htm |